MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type…
| Price | $0.79 |
|---|---|
| Market cap | $33.24M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Exchange | NASDAQ |
| 52-week range | 0.6-2.45 |
| Beta | 1.54 |
Explore MIRA's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.